Rheumatology · Sugar Land, TX
NPI
1124073655
Since 2006
Specialty
Rheumatology
Code 174400000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
1429 Highway 6 South, Ste 103
Sugar Land, TX, 77478
Phone (713) 273-5881
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.7M
176,573 services
Medicare patients, 2024
309
Average age 73
Drug cost, 2024
$3.9M
4,741 prescriptions
Company payments, 2025
$37.98
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Grace A Makhlouf was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 95,600 times for 28 patients. In total Grace A Makhlouf billed 176,573 services in 71 codes, and Medicare paid $2.7M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-03-01.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 95,600 | 28 | $3.60 | $344K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 60,450 | 83 | $33.78 | $2.0M |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 10,300 | 16 | $9.32 | $96K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 3,060 | 14 | $24.45 | $75K |
| 96413 Chemotherapy Administration | Office | 920 | 110 | $87.14 | $80K |
| 36415 Venipuncture Blood Collection | Office | 801 | 277 | $8.61 | $6,894 |
| 85652 Clinical Chemistry | Office | 787 | 280 | $2.64 | $2,076 |
| 85025 Blood Count | Office | 775 | 278 | $7.57 | $5,870 |
| 86140 Clinical Chemistry | Office | 774 | 280 | $5.06 | $3,913 |
| 82565 Clinical Chemistry | Office | 769 | 275 | $4.99 | $3,837 |
| 80076 Clinical Chemistry | Office | 729 | 275 | $7.97 | $5,809 |
| 99213 Office E&M - Established | Office | 590 | 293 | $57.09 | $34K |
| 96401 Chemotherapy Administration | Office | 479 | 29 | $48.37 | $23K |
| 96415 Chemotherapy Administration | Office | 56 | 14 | $18.77 | $1,051 |
| 82607 Clinical Chemistry | Office | 34 | 33 | $14.78 | $503 |
By year: 2022 $3.4M for 227,362 services; 2023 $3.1M for 206,599 services; 2024 $2.7M for 176,573 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 801 | 277 | $8.61 | $6,894 |
| 85652 Clinical Chemistry | 787 | 280 | $2.64 | $2,076 |
| 85025 Blood Count | 775 | 278 | $7.57 | $5,870 |
| 86140 Clinical Chemistry | 774 | 280 | $5.06 | $3,913 |
| 82565 Clinical Chemistry | 769 | 275 | $4.99 | $3,837 |
| 80076 Clinical Chemistry | 729 | 275 | $7.97 | $5,809 |
| 82607 Clinical Chemistry | 34 | 33 | $14.78 | $503 |
| 82746 Clinical Chemistry | 33 | 32 | $14.41 | $476 |
| 84466 Clinical Chemistry | 32 | 30 | $12.14 | $389 |
| 83540 Clinical Chemistry | 32 | 30 | $6.16 | $197 |
Medicare prescription drug claims, 2024
In 2024, the drug Grace A Makhlouf prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 1,042 prescriptions and refills. In total Grace A Makhlouf wrote 4,741 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 1,042 | 2,922 | 338 | $51K |
| Leflunomide Generic | 553 | 1,494 | 173 | $19K |
| Sulfasalazine Dr Sulfasalazine | 453 | 1,273 | 154 | $32K |
| Methotrexate Methotrexate Sodium | 313 | 851 | 107 | $8,809 |
| Gabapentin Generic | 263 | 715 | 94 | $7,223 |
| Azathioprine Generic | 239 | 663 | 72 | $9,799 |
| Methylprednisolone Generic | 170 | 279 | 103 | $2,404 |
| Duloxetine Hcl Generic | 125 | 363 | 46 | $3,765 |
| Celecoxib Generic | 115 | 330 | 46 | $6,021 |
| Enbrel Etanercept | 110 | 119 | 13 | $893K |
| Sulfasalazine Generic | 87 | 236 | 32 | $3,475 |
| Prednisone Generic | 79 | 211 | 25 | $735 |
| Diclofenac Sodium Generic | 69 | 177 | 30 | $2,910 |
| Tizanidine Hcl Generic | 66 | 192 | 34 | $1,521 |
| Meloxicam Generic | 64 | 183 | 31 | $575 |
Brand drugs: - claims; generic drugs: 3,764 claims; opioid claims: 18.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Grace A Makhlouf $37.98 ($37.98 in general payments such as food, travel and fees) from 1 company. The largest payer was E.R. Squibb & Sons, L.L.C. with $37.98.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $37.98 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.